SOURCE-LINKED STUDY SUMMARY
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
Abstract summarized · Quality not appraised
- Studied
- SURPASS-4 randomized adults with type 2 diabetes and high cardiovascular risk to once-weekly tirzepatide or titrated insulin glargine.
- Who / model
- Participants had inadequately controlled type 2 diabetes despite oral glucose-lowering medications and established or high cardiovascular risk.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- Found
- At one year, tirzepatide lowered HbA1c more than glargine and caused less hypoglycemia; adjudicated cardiovascular events were not increased.
- Limits
- The trial used an open-label design.
Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary
Research findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1016/s0140-6736(21)02188-7